| 1 |
34762994 | Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. | 2022 Feb 1 |
1 |
| 2 |
35089089 | The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. | 2022 Jan |
2 |
| 3 |
35218983 | Correlation of poly (adenosine diphosphate[ADP]-ribose) polymerase expression and prognosis in ovarian cancer: A systematic review and meta-analysis. | 2022 Apr |
1 |
| 4 |
35274707 | Homologous Recombination Deficiency: Concepts, Definitions, and Assays. | 2022 Mar 11 |
1 |
| 5 |
35386537 | Conceptual Framework for SARS-CoV-2-Related Lymphopenia. | 2022 |
1 |
| 6 |
35540097 | PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension. | 2022 Apr |
1 |
| 7 |
35557035 | Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). | 2022 May 3 |
1 |
| 8 |
33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | 2021 Apr 15 |
1 |
| 9 |
33420642 | Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. | 2021 Jun |
1 |
| 10 |
33452452 | Clinical implications of genomic alterations in metastatic prostate cancer. | 2021 Jun |
1 |
| 11 |
33482196 | Poly(ADP-ribose) polymerase 1 regulates mitochondrial DNA repair in an NAD-dependent manner. | 2021 Jan-Jun |
1 |
| 12 |
33545804 | Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report. | 2021 Jan |
1 |
| 13 |
33576344 | Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study. | 2021 |
1 |
| 14 |
33579802 | Molecular Imaging: PARP-1 and Beyond. | 2021 Jun 1 |
1 |
| 15 |
33781305 | Prostate cancer and PARP inhibitors: progress and challenges. | 2021 Mar 29 |
2 |
| 16 |
33884961 | In vivo visualization of PARP inhibitor pharmacodynamics. | 2021 Apr 22 |
1 |
| 17 |
33927108 | Next-generation sequencing for the management of sarcomas with no known driver mutations. | 2021 Jul 1 |
1 |
| 18 |
33986609 | PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis. | 2021 |
1 |
| 19 |
34021367 | Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. | 2021 Aug |
1 |
| 20 |
34025781 | The role of PARP inhibitors in BRCA mutated pancreatic cancer. | 2021 |
1 |
| 21 |
34493147 | Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. | 2021 Nov |
1 |
| 22 |
34636047 | Running out of time: The case of patient advocacy for ovarian cancer patients' access to PARP inhibitors. | 2021 Nov |
1 |
| 23 |
34761497 | MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. | 2021 Dec |
1 |
| 24 |
34866915 | Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation. | 2021 |
1 |
| 25 |
32283836 | Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells. | 2020 Apr 9 |
1 |
| 26 |
32368391 | CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. | 2020 |
1 |
| 27 |
32523631 | Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. | 2020 |
1 |
| 28 |
32639661 | Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. | 2020 Sep |
1 |
| 29 |
32782491 | PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. | 2020 |
1 |
| 30 |
32848588 | Molecular Crosstalk Between Circadian Rhythmicity and the Development of Neurodegenerative Disorders. | 2020 |
1 |
| 31 |
32936912 | Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. | 2020 Nov 10 |
1 |
| 32 |
32945484 | Erastin induces apoptotic and ferroptotic cell death by inducing ROS accumulation by causing mitochondrial dysfunction in gastric cancer cell HGC‑27. | 2020 Oct |
1 |
| 33 |
33063092 | Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. | 2020 Oct 30 |
1 |
| 34 |
33352773 | PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. | 2020 Dec 19 |
2 |
| 35 |
31042381 | Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. | 2019 Jun 13 |
4 |
| 36 |
31102368 | Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells | 2019 Sep |
2 |
| 37 |
31283415 | Fallopian Tube Carcinoma. | 2019 Jul |
1 |
| 38 |
31562799 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. | 2019 Dec 19 |
1 |
| 39 |
31807024 | Effects Of Adenosine On Apoptosis Of Ovarian Cancer A2780 Cells Via ROS And Caspase Pathways. | 2019 |
1 |
| 40 |
29784743 | New Therapies for Ovarian Cancer. | 2018 May |
1 |
| 41 |
30385548 | Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. | 2018 Nov 2 |
1 |
| 42 |
23454167 | NAD(+) influx through connexin hemichannels prevents poly(ADP-ribose) polymerase-mediated astrocyte death. | 2013 Apr 19 |
1 |
| 43 |
22297980 | Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. | 2012 Feb 1 |
1 |
| 44 |
16631419 | Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes. | 2006 May |
1 |
| 45 |
14684303 | The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). | 2004 Jan 5 |
4 |
| 46 |
11149897 | Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. | 2001 Jan |
3 |
| 47 |
8535170 | Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked resistance of HL-60 cells to various apoptosis-inducers. | 1995 Sep |
2 |